MetLife Reports Strong Q4 & Full Year 2025 Results, Exceeds Key Targets, Maintains Positive 2026 Outlook
MET sits 20% above its 52-week low of $65.21.
Summary
MetLife announced robust fourth quarter and full year 2025 financial results, surpassing several key targets including adjusted EPS growth, free cash flow ratio, and direct expense ratio, while also providing a confident outlook for 2026.
Key Events · Earnings and Guidance · MET
-
Strong Full Year Performance
Achieved 10% adjusted EPS growth and 16% adjusted return on equity for 2025, meeting or exceeding targets.
-
Significant Capital Return
Returned nearly $4.4 billion to shareholders in 2025 through share repurchases and dividends.
-
Positive 2026 Outlook
Reaffirmed near-term annual targets for double-digit adjusted EPS growth and adjusted ROE of 15-17%.
-
Operational Efficiency
Beat direct expense ratio target for 2025 and set a new target of 12.1% for 2026.
Analysis · MET · Finance
MetLife's latest 8-K filing details a strong financial performance for both Q4 and the full year 2025, characterized by double-digit adjusted EPS growth and a healthy adjusted return on equity. The company successfully exceeded its free cash flow and direct expense ratio targets, demonstrating effective operational management. Furthermore, the significant capital return to shareholders underscores a solid financial position. The reaffirmed positive outlook for 2026, including continued double-digit adjusted EPS growth and ROE targets, provides investors with confidence in the company's strategic direction and ability to navigate market uncertainties. This comprehensive report indicates a well-managed company delivering on its commitments and setting a positive tone for the upcoming year.
At the time of this filing, MET was trading at $78.01 on NYSE in the Finance sector, with a market capitalization of approximately $51.4B. The 52-week trading range was $65.21 to $87.39. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.